Sign up
Pharma Capital

Futura Medical begins recruitment for MED2002 safety trial

James Barder, chief executive of Futura Medical plc (LON:FUM), tells Proactive they've begun recruitment for a pharmacokinetic study of their lead product, MED2002.

It's a prelude to starting phase III trials of the breakthrough gel for erectile dysfunction.

Data from 40 men will determine the doses used in the final-stage clinical assessment, which will kick off as “soon as practicable” after the current programme.

 

View full FUM profile

Futura Medical plc. Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.